Companies › C Ray Therapeutics
4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Ophthalmology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RTx-015 Gene therapy delivering an optogenetic gene to retinal cells to produce light-responsive p | – | Phase 2 | Retinitis Pigmentosa (RP); Retinitis Pigmentosa | Oct 2028 |
| TRDC002 PSMA-targeting radiotracer (64Cu-labeled) | PSMA | Phase 1 | Prostate Cancer | Dec 2026 |
| TRC003 225Ac-labeled PSMA-targeted alpha particle therapy (targeted alpha therapy) | PSMA | Phase 1 | Prostate Cancer | Dec 2027 |
| RTx-021 Optogenetic gene therapy | – | Phase 1 | Stargardt Disease | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07236112 | TRDC002 | Phase 1 | Prostate Cancer | Oncology | Dec 2026 |
| NCT07567521 | TRC003 | Phase 1 | Prostate Cancer | Oncology | Dec 2027 |
| NCT07901751 | RTx-015 | Phase 2 | Retinitis Pigmentosa (RP) | Ophthalmology | Oct 2028 |
| NCT06460844 | RTx-015 | Phase 1 | Retinitis Pigmentosa | Ophthalmology | Oct 2030 |
| NCT07439887 | RTx-021 | Phase 1 | Stargardt Disease | Ophthalmology | Dec 2030 |
Norroy Bioscience Lantheus Medical Imaging POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Clarity Pharmaceuticals Fusion Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.